9 minute read
May 7, 2024
Sage Therapeutics/Biogen Secure FDA Approval for Zuranolone (ZURZUVAE) as the First Oral Treatment for Postpartum Depression
zuranolone
oral CNS GABA receptor positive allosteric modulator FDA-approved for postpartum depression as Zurzuvae™ optimized from the endogenous neurosteroid allopregnanolone Sage Therapeutics, Cambridge, MA; Biogen, Cambridge, MA
Loading...
